This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Charles O'Neill, PhD
Vice President, Early Drug Development Solutions at BioMarin Pharmaceutical


Chuck joined BioMarin in 2003 and currently serves as the Vice President of Early Drug Development Solutions.  From 2007 to 2020, Chuck served as VP, Pharmacological Sciences overseeing the nonclinical development of BioMarin’s late-stage research and clinical drug candidates, as well as supporting BioMarin’s commercial products.  From 1996 through 2003, Chuck held increasing roles of responsibilities in Safety Assessment at Genentech, Inc. where he led nonclinical development for the anti-angiogenic monoclonal antibody, Avastin™ and oversaw the nonclinical development for Lucentis™, a treatment for age-related macular degeneration.  From 1995 to 1996 Chuck was an Assistant Research Professor at the UC Davis, School of Medicine and is currently an Adjunct Assistant Professor in the Pharmacology and Toxicology Graduate Group.  Chuck was a Postdoctoral Fellow at the NIH, NHLBI from 1992 to 1995.  Chuck has contributed to 65 regulatory submissions and has coauthored over 80 peer-reviewed publications.  Dr. O'Neill received his Ph.D. in Veterinary Pharmacology and Toxicology from UC Davis.

Agenda Sessions

  • Characterization of Novel Exon-51 Skipping Oligonucleotides that Safely Rescues Dystrophin Expression in a Severe Model of Duchenne Muscular Dystrophy